EASL 2025: hepatitis B
International EASL Current
EASL Clinical Practice Guidelines on the management of hepatitis B virus infection
European Association for the Study of the Liver. J Hepatol. 2025
DOI 10.1016/j.jhep.2025.03.018 · Summary checked against the source: 2026-11
Replaces EASL 2017. Citations give the Oxford level of evidence and the strength (strong or weak) as written, and the page in the Journal of Hepatology article.
At a glance
- Assess every HBsAg-positive person: liver disease stage by non-invasive tests (elastography), abdominal ultrasound, and test for HDV, HCV and HIV. [strong · p. 6, 8]
- Treat chronic hepatitis B with HBV DNA ≥2,000 IU/mL and ALT >ULN and/or significant fibrosis. [LoE 1, strong · p. 13]
- Treat any cirrhosis with detectable HBV DNA, whatever the level or ALT. [LoE 3, strong · p. 13]
- HBeAg-positive or -negative chronic infection: individual decision; treat if raised HCC risk, extrahepatic disease, immunosuppression, or to prevent transmission. [p. 15, 17]
- Options: a nucleos(t)ide analogue (entecavir, tenofovir DF or alafenamide) or PEG-IFNα. [LoE 1, strong · p. 19]
- Pregnancy: tenofovir if HBV DNA ≥200,000 IU/mL, ideally started before the third trimester; breastfeeding is fine. [LoE 1, strong · p. 34]
- HCC surveillance: ultrasound every 6 months in at-risk patients, continued even after viral suppression or HBsAg loss. [LoE 2, strong · p. 31]
Diagnosis and staging
- Baseline tests: HBsAg (quantitative), HBeAg and anti-HBe, HBV DNA, ALT; anti-HDV, anti-HCV and anti-HIV in everyone (strong). Anti-HBc IgM if acute hepatitis is suspected. [Table 5 · p. 6]
- Assess the liver in every HBsAg-positive person: ultrasound at diagnosis and non-invasive fibrosis tests; biopsy only for uncertainty or discordant results. [strong · p. 8]
| Liver stiffness (VCTE) | Fibrosis |
|---|---|
| >7 kPa | Significant (F2+) |
| >8 kPa | Advanced (F3+) |
| >11 kPa | Cirrhosis (F4) |
Adapted from EASL 2025 Table 6 [p. 8]
Monitoring untreated patients: ALT and HBV DNA every 3–6 months in the first year, then every 6–12 months; HBsAg and (if HBeAg-positive) HBeAg and anti-HBe yearly; repeat non-invasive fibrosis tests. [strong · p. 9]
The disease phases keep the EASL names: HBeAg-positive chronic infection and chronic hepatitis, HBeAg-negative chronic infection and chronic hepatitis, and the HBsAg-negative phase (occult or resolved infection).
Who to treat
Strong recommendations [p. 13–17]
- Chronic hepatitis B (HBeAg-positive or negative) with HBV DNA ≥2,000 IU/mL and ALT >ULN and/or significant fibrosis. [LoE 1, strong · p. 13]
- Cirrhosis with any detectable HBV DNA. [LoE 3, strong · p. 13]
- Chronic infection (HBeAg-positive or negative) with an increased HCC risk or extrahepatic manifestations. [LoE 3–4, strong · p. 15, 17]
- Chronic infection before immunosuppression, or when immunocompromised. [LoE 2, strong · p. 15, 17]
Weak recommendations [p. 13–17]
- Advanced fibrosis (≥F3 or LSM >8 kPa) with detectable HBV DNA, whatever the level. [LoE 5, weak · p. 13]
- HBV DNA <2,000 with persistently raised ALT, after considering other liver diseases. [LoE 5, weak · p. 13]
- Selected people with chronic infection, to prevent transmission. [LoE 3–4, weak · p. 15, 17]
Treatment
| Nucleos(t)ide analogue (entecavir, TDF, TAF) | PEG-IFNα | |
|---|---|---|
| Route and duration | Oral, long term (usually indefinite) | Weekly injection, finite (48 weeks) |
| Effect | Suppresses HBV DNA in almost everyone; HBsAg loss is rare | Immune modulation; higher HBsAg loss in selected patients |
| Resistance | Very low with entecavir and tenofovir | None |
| Notes | Check kidney function before and during; consider previous NA exposure | Use predictors and stopping rules at weeks 12 and 24; not in decompensated cirrhosis |
Adapted from EASL 2025 Tables 9–10 and recommendations [p. 19–29]
- Goal: sustained HBV DNA suppression; ideal endpoint HBsAg loss ("functional cure"). [p. 12]
- Cirrhosis: aim for undetectable HBV DNA by 12 months; otherwise adjust. Partial response or non-response: check adherence first. [LoE 3, strong; LoE 1, strong · p. 24]
- Stopping NAs: stop after confirmed HBsAg loss. HBeAg-positive without advanced disease: may stop 12 months after HBeAg seroconversion with undetectable DNA, under close monitoring. Use HBsAg levels to select HBeAg-negative patients for stopping. [LoE 2 · p. 25]
- De novo PEG-IFNα + NA combination isn't generally recommended; PEG-IFN add-on in selected HBeAg-negative patients on NA with low HBsAg. [LoE 2, weak · p. 29]
Special populations
| Group | Recommendation |
|---|---|
| Acute hepatitis B with impaired synthetic function | NA, managed with a transplant centre (LoE 2, strong) |
| Pregnancy | Continue tenofovir; switch entecavir or PEG-IFN to tenofovir. Untreated: treat for chronic hepatitis, HBV DNA ≥200,000 IU/mL, or HBeAg-positive where DNA testing isn't available. Start before the third trimester. Breastfeeding allowed (LoE 1–2, strong) |
| Newborn of HBsAg-positive mother | Vaccine within 12 hours plus HBIG (LoE 1, strong) |
| HIV co-infection | Treat HBV regardless of ALT or HBV DNA, with a tenofovir-containing ART; never stop it (LoE 2, strong) |
| HCV co-infection | Treat HCV with DAAs; NA if the patient meets HBV criteria or to prevent reactivation (LoE 2, strong) |
| Hepatitis D | PEG-IFNα or bulevirtide; NA if cirrhotic or HBV DNA ≥2,000; transplant assessment if decompensated (LoE 2–5) |
| Decompensated cirrhosis | NA, no PEG-IFN, transplant assessment (LoE 1, strong) |
Adapted from EASL 2025 [p. 34–38, 49]
Immunosuppression and reactivation
- Test HBsAg and anti-HBc before any immunosuppression. [LoE 1, strong · p. 40]
- HBsAg-positive, high or moderate risk: NA prophylaxis. Low risk: HBV DNA every 3 months, or prophylaxis if monitoring isn't feasible. [LoE 1–2, strong · p. 40]
- HBsAg-negative, anti-HBc-positive: prophylaxis for high-risk immunosuppression (e.g. rituximab and other B-cell depletion); otherwise monitor. [LoE 2, strong · p. 40]
- Continue prophylaxis 6–12 months after stopping immunosuppression, and ≥18 months after B-cell depleting therapy. [LoE 3, strong · p. 40]
Clinical pearls
- Treat: DNA ≥2,000 + raised ALT and/or significant fibrosis; any cirrhosis with detectable DNA.
- First line: entecavir, TDF or TAF (high barrier to resistance), or PEG-IFNα.
- Pregnancy: tenofovir if DNA ≥200,000 IU/mL; birth-dose vaccine + HBIG within 12 h.
- Rituximab carries the highest reactivation risk: give prophylaxis even if HBsAg-negative, anti-HBc-positive.
- HCC surveillance: ultrasound 6-monthly.
Classes and levels of evidence
How EASL 2025 grades its recommendations. Adapted from EASL 2025 Tables 1–3 [p. 2–3]. Hover over any class or level cited on this page to see what it means.
| Class | Meaning | Wording used |
|---|---|---|
| LoE 1 | Systematic review of RCTs or n-of-1 trials (highest level) | |
| LoE 2 | Individual RCT, or observational study with dramatic effect | |
| LoE 3 | Non-randomised controlled cohort or follow-up study | |
| LoE 4 | Case series, case-control or historically controlled studies | |
| LoE 5 | Mechanism-based reasoning or expert opinion | |
| A1 | High-quality evidence (further research very unlikely to change confidence); strong recommendation | |
| A2 | High-quality evidence; weak recommendation | |
| B1 | Moderate-quality evidence (further research may change the estimate); strong recommendation | |
| B2 | Moderate-quality evidence; weak recommendation | |
| C1 | Low-quality evidence (any estimate of effect is uncertain); strong recommendation | |
| C2 | Low-quality evidence; weak recommendation |
| Level | Meaning |
|---|---|
| Strong recommendation | Wording: shall, should, is recommended (or should not). Based on evidence, consistency, risk–benefit, patient preference, ethics and feasibility |
| Weak or open recommendation | Wording: can, may, is suggested (or may not) |
Recent EASL guidelines rate evidence with Oxford Centre for Evidence-Based Medicine levels (1 strongest to 5) and grade each recommendation strong ("should", "is recommended") or weak/open ("can", "may", "is suggested"). Each also records the panel's consensus: strong consensus ≥95%, consensus 75–95%. EASL 2020 HCV instead uses evidence A–C with strength 1–2 (written A1, B2 and so on).